Eli Lilly and Company (LLY) Expected to Post Quarterly Sales of $5.50 Billion
Analysts expect Eli Lilly and Company (NYSE:LLY) to report sales of $5.50 billion for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Eli Lilly and’s earnings, with estimates ranging from $5.46 billion to $5.57 billion. Eli Lilly and reported sales of $5.19 billion in the same quarter last year, which indicates a positive year over year growth rate of 6%. The company is expected to report its next earnings report before the market opens on Tuesday, October 24th.
According to Zacks, analysts expect that Eli Lilly and will report full-year sales of $5.50 billion for the current year, with estimates ranging from $22.30 billion to $22.66 billion. For the next financial year, analysts expect that the firm will report sales of $22.85 billion per share, with estimates ranging from $22.16 billion to $23.35 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Eli Lilly and.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, topping the Zacks’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The company had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. During the same period in the prior year, the business posted $0.86 EPS. The company’s quarterly revenue was up 7.8% on a year-over-year basis.
A number of analysts recently weighed in on the stock. BidaskClub raised shares of Eli Lilly and from a “sell” rating to a “hold” rating in a research report on Wednesday, June 14th. Barclays PLC increased their price target on shares of Eli Lilly and from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Tuesday, July 4th. BMO Capital Markets reissued a “sell” rating and set a $73.00 price target on shares of Eli Lilly and in a research report on Friday, August 4th. Berenberg Bank reissued a “buy” rating and set a $100.00 price target on shares of Eli Lilly and in a research report on Thursday, July 27th. Finally, Jefferies Group LLC reissued a “buy” rating and set a $96.00 price target (up from $93.00) on shares of Eli Lilly and in a research report on Thursday, July 13th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $88.07.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 180,000 shares of the business’s stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $81.06, for a total value of $14,590,800.00. Following the completion of the sale, the insider now owns 123,865,804 shares in the company, valued at $10,040,562,072.24. The sale was disclosed in a document filed with the SEC, which is available through this link. In the last quarter, insiders sold 825,000 shares of company stock valued at $68,456,650. 0.20% of the stock is owned by company insiders.
Institutional investors have recently added to or reduced their stakes in the company. Joel Isaacson & Co. LLC grew its holdings in Eli Lilly and by 1.5% during the first quarter. Joel Isaacson & Co. LLC now owns 3,364 shares of the company’s stock worth $283,000 after acquiring an additional 50 shares during the period. Russell Investments Group Ltd. grew its holdings in Eli Lilly and by 7.8% in the second quarter. Russell Investments Group Ltd. now owns 671,327 shares of the company’s stock valued at $55,258,000 after purchasing an additional 48,706 shares during the last quarter. Stephens Inc. AR grew its holdings in Eli Lilly and by 4.5% in the first quarter. Stephens Inc. AR now owns 44,023 shares of the company’s stock valued at $3,703,000 after purchasing an additional 1,901 shares during the last quarter. Blair William & Co. IL grew its holdings in Eli Lilly and by 13.1% in the first quarter. Blair William & Co. IL now owns 262,258 shares of the company’s stock valued at $21,974,000 after purchasing an additional 30,299 shares during the last quarter. Finally, BlackRock Inc. grew its holdings in Eli Lilly and by 2,628.5% in the first quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock valued at $5,236,731,000 after purchasing an additional 59,978,664 shares during the last quarter. Institutional investors and hedge funds own 75.77% of the company’s stock.
Shares of Eli Lilly and (NYSE LLY) opened at 83.09 on Friday. Eli Lilly and has a 12 month low of $64.18 and a 12 month high of $86.72. The firm’s 50-day moving average is $80.90 and its 200 day moving average is $82.06. The firm has a market capitalization of $87.66 billion, a P/E ratio of 35.95 and a beta of 0.34.
The firm also recently announced a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Tuesday, August 15th were paid a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.50%. The ex-dividend date was Friday, August 11th. Eli Lilly and’s payout ratio is 90.04%.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.